- Details
- Pedro Barata interviews Nourhan El Ahmar to discuss the significant work conducted by El Ahmar's team. The work focused on a subgroup analysis of the HCRN GU16-260 platform study that investigated the use of nivolumab with ipilimumab as salvage therapy for patients with advanced renal cell carcinoma. El Ahmar delves into the specifics of the trial, explaining how their lab played a crucial role in...
|
- Details
- Zach Klaassen interviews Cristiane Bergerot to explore health-related quality of life (HRQoL) in renal cell carcinoma patients, with Bergerot asserting that existing measures often overlook relevant aspects. She elaborates on her study, examining patient's perceptions of common HRQoL measures like FKSI-19, EORTC QLQ-C30, and EQ-5D. Involving 147 participants from the US, Brazil, and Europe, the st...
|
- Details
- Zach Klaassen interviews Sarah Psutka about her Phase I/II trial focusing on using acupuncture to mitigate the toxic effects of Bacillus Calmette-Guerin (BCG) therapy for non-muscle invasive bladder cancer. Psutka explains that while BCG is an essential treatment for high-risk cases, it triggers a severe inflammatory response that can lead to an array of symptoms, including urinary urgency, painfu...
|
- Details
- Zach Klaassen hosts a high-level discussion with Christian Gratzke about the potential practice-changing outcomes of the EMBARK trial, specifically the impressive results of intensified treatment in high-risk patients. Dr. Gratzke suggests that intermittent hormone treatment could also be effective. The conversation also touches on enzalutamide monotherapy as a standalone treatment and how its suc...
|
- Details
- Alicia Morgans engages with Silke Gillessen to discuss the upcoming APCCC conference in 2024. The conference seeks to address some of the major questions in clinical practice such as the management of biochemical relapse after radical prostatectomy and the application of novel endocrine agents plus PARP inhibitors in first line mCRPC treatments. Side effects and their management, especially those...
|
- Details
- Neeraj Agarwal articulates his vision for the future of treating metastatic castration-sensitive prostate cancer (CSPC). Agarwal delves into the remarkable therapeutic advancements in the past decade, notably, the shift to doublet and triplet therapies. Despite these developments, he draws attention to the underutilization of such treatments in real-world settings due to various barriers. Primaril...
|
- Details
- In a discussion with Alicia Morgans, Paul Nguyen highlights the advancing role of predictive biomarkers in prostate cancer treatment. He distinguishes between prognostic and predictive biomarkers, emphasizing the unique value of the latter in tailoring the right amount of treatment for individual patients. They focus on the development of a commercial test by Artera that predicts responses to shor...
|
- Details
- In this conversation, Alicia Morgans and Neeraj Agarwal discuss the TALAPRO-2 trial, a phase three study investigating the effectiveness of combining ADT plus enzalutamide plus talazoparib in treating first line metastatic castrate-resistant prostate cancer. Agarwal presents the study's quality of life data at ASCO 2023, revealing the experimental arm significantly delayed the deterioration of pat...
|
- Details
- Alicia Morgans interviews Matthew Smith about the ARASENS Study and its implications for patients focusing on the study's secondary endpoints, including time to pain progression and skeletal-related events, which are crucial for understanding patient well-being. He emphasizes that the study included a diverse range of patients with varying disease characteristics, and the overall survival benefit...
|
- Details
- In a discussion between Alicia Morgans and Alberto Bossi, they delved into the PEACE-1 data. Professor Bossi outlined the European study initiated by himself and Karim Fizazi, focusing on the potential impact of radiotherapy and abiraterone on the prognosis of metastatic prostate cancer patients. Discussing the study's results, Professor Bossi revealed no overall survival benefit from radiotherapy...
|
